Pacira BioSciences
PCRX
259 hedge funds and large institutions have $2.75B invested in Pacira BioSciences in 2021 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 95 increasing their positions, 90 reducing their positions, and 25 closing their positions.
192% more call options, than puts
Call options by funds: $6.09M | Put options by funds: $2.09M
6% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 90
0% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 25
1% less funds holding
Funds holding: 262 → 259 (-3)
1.62% less ownership
Funds ownership: 112.14% → 110.52% (-1.6%)
8% less capital invested
Capital invested by funds: $2.99B → $2.75B (-$242M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$53.9M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$11.8M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$5.51M |
| 4 |
SCM
Spyglass Capital Management
San Francisco,
California
|
+$5.39M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$4.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$22.2M |
| 2 |
Two Sigma Investments
New York
|
-$14.8M |
| 3 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
-$13.7M |
| 4 |
DM
Deerfield Management
New York
|
-$10.4M |
| 5 |
Morgan Stanley
New York
|
-$9.9M |
PCRX Hedge Fund Activity: Q3 2021 in Review
259 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2021, worth a combined $2.75B — down 8.1% from $2.99B a quarter earlier.
Fund positioning in PCRX was balanced in Q3 2021: 25 funds opened new positions, 25 closed out, 95 added to existing stakes and 90 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $53.9M. The largest seller was Wells Fargo, cutting an estimated $22.2M.
- 259 institutional investors held Pacira BioSciences (PCRX) as of Q3 2021, down from 262 in Q2 2021.
- Funds reported $2.75B of Pacira BioSciences stock for Q3 2021, down 8.1% quarter-over-quarter.
- 25 funds opened new Pacira BioSciences positions in Q3 2021 and 25 closed out, a net change of 0 holders.
- The largest Pacira BioSciences buyer in Q3 2021 was Armistice Capital, an estimated $53.9M added.
- The largest Pacira BioSciences seller in Q3 2021 was Wells Fargo, an estimated $22.2M sold.
Based on aggregated 13F filings for Q3 2021.